A new board has been formed to support and expand the scientific knowledge base for vitamin K2.
Kappa Bioscience, manufacturer of vitamin K2 under the brand name K2VITAL, has announced the formation of a Scientific and Medical Advisory Board, said to reflect Kappa’s unique commitment to growing awareness of the rapidly expanding range of benefits associated with vitamin K2 in the form of Menaquinone 7 (MK-7).
It will include world authorities in relevant fields of science, including cardiology, immunology, kinesiology, and molecular nutrition, and will set a new standard for the scientific support and advancement of emerging nutritional compounds.
“The formation of Kappa’s Scientific and Medical Advisory Board is a further demonstration of the company’s commitment to maintaining its leadership position in the K2 sector and to bringing its remarkable health benefits to a growing number of consumers worldwide,” commented Egil Greve, Kappa’s Chief Executive Officer.
“We are honoured to have attracted this esteemed group of scientists. The top-class experts together have authored over 700 scientific papers. We are confident that with their help, awareness of vitamin K2 and its scope of benefits will rapidly accelerate.”
Trygve Bergeland, Ph.D., Vice President Science, will lead the group and coordinate their activities with Kappa’s current research initiatives already underway. “Together, we believe that we will be able to establish a recommended daily intake for K2 for all people as an essential nutrient, as well as raising awareness of its role in maintaining health,” he advised.
